By George W. Evans, an Associate General Counsel, Pfizer Inc., and General Counsel, Pfizer Pharmaceuticals Group, and Arnold I. Friede, a Senior Corporate Counsel at Pfizer Inc., who formerly served in the FDA Chief Counsel’s Office.
By George W. Evans, an Associate General Counsel, Pfizer Inc., and General Counsel, Pfizer Pharmaceuticals Group, and Arnold I. Friede, a Senior Corporate Counsel at Pfizer Inc., who formerly served in the FDA Chief Counsel’s Office.
This site uses cookies for performance, site traffic analysis, and social media purposes. Find out more about our cookie policy here. You can adjust your preferences in cookie settings.